Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer

Ruirui Wang; Li Yang; Chaoqi Zhang; Ruijie Wang; Zhen Zhang; Qianyi He; Xinfeng Chen; Bin Zhang; Zhihai Qin; Liping Wang; Yi Zhang

doi:10.1080/2162402X.2018.1461303

Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer

Ruirui Wang, Li Yang, Chaoqi Zhang, Ruijie Wang, Zhen Zhang, Qianyi He, Xinfeng Chen, Bin Zhang, Zhihai Qin, Liping Wang, Yi Zhang^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Non-small cell lung cancer (NSCLC) accounts for the majority of all lung cancer cases, which is the leading cause of cancer deaths worldwide. IL-17░A, the major effector cytokine derived from Th17 cells, is a key cytokine in tumor pathogenesis and modulates tumor progression. We aimed to identify whether IL-17░A derived from Th17 cells promotes the progression of NSCLC. Here we found that the level of Th17 cells was increased in NSCLC and IL-17░A was mainly produced by CD4⁺ cells (Th17 cells) in NSCLC. IL-17░A enhanced the migration, invasion and stemness of NSCLC via STAT3/NF-κB/Notch1 signaling. Blockade of this signaling inhibited the migration, invasion and stemness of NSCLC mediated by IL-17░A. Th17 cells in NSCLC were closely associated with poor prognosis of NSCLC patients. Our results indicated that Th17 cell-derived IL-17░A plays an important role in tumor progression of NSCLC via STAT3/NF-κB/Notch1 signaling. Therefore, therapeutic strategies against this pathway would be valuable to be developed for NSCLC treatment.

Original language	English (US)
Article number	e1461303
Journal	OncoImmunology
Volume	7
Issue number	11
DOIs	https://doi.org/10.1080/2162402X.2018.1461303
State	Published - Nov 2 2018

Keywords

Th17 cells
Tumor microenvironment
interleukin-17A (IL-17A)
non-small cell lung cancer (NSCLC)
tumor progression

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/2162402X.2018.1461303

Cite this

@article{a5f0611004df4bf688b135b06bdc5e5a,

title = "Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer",

abstract = "Non-small cell lung cancer (NSCLC) accounts for the majority of all lung cancer cases, which is the leading cause of cancer deaths worldwide. IL-17░A, the major effector cytokine derived from Th17 cells, is a key cytokine in tumor pathogenesis and modulates tumor progression. We aimed to identify whether IL-17░A derived from Th17 cells promotes the progression of NSCLC. Here we found that the level of Th17 cells was increased in NSCLC and IL-17░A was mainly produced by CD4+ cells (Th17 cells) in NSCLC. IL-17░A enhanced the migration, invasion and stemness of NSCLC via STAT3/NF-κB/Notch1 signaling. Blockade of this signaling inhibited the migration, invasion and stemness of NSCLC mediated by IL-17░A. Th17 cells in NSCLC were closely associated with poor prognosis of NSCLC patients. Our results indicated that Th17 cell-derived IL-17░A plays an important role in tumor progression of NSCLC via STAT3/NF-κB/Notch1 signaling. Therefore, therapeutic strategies against this pathway would be valuable to be developed for NSCLC treatment.",

keywords = "Th17 cells, Tumor microenvironment, interleukin-17A (IL-17A), non-small cell lung cancer (NSCLC), tumor progression",

author = "Ruirui Wang and Li Yang and Chaoqi Zhang and Ruijie Wang and Zhen Zhang and Qianyi He and Xinfeng Chen and Bin Zhang and Zhihai Qin and Liping Wang and Yi Zhang",

note = "Funding Information: This study was supported by grants from the National Natural Science Foundation of China (No.81171986, No. 81602024, No. 81771781), Funding from State's Key Project of Research and Development Plan (No. 2016YFC1303500), Research Grant from the Ministry of Public Health (No.201501004), Fundings for Creative Research Team of Henan Province, Creative Research Team of Higher Education of Henan Province. Funding Information: This study was supported by grants from the National Natural Science Foundation of China (No. 81171986, No. 81602024, No. 81771781), Funding from State{\textquoteright}s Key Project of Research and Development Plan (No. 2016YFC1303500), Research Grant from the Ministry of Public Health (No. 201501004), Fundings for Creative Research Team of Henan Province, Creative Research Team of Higher Education of Henan Province. This study was supported by Creative Research Team of Henan Province Creative Research Team of Higher Education of Henan Province National Natural Science Foundation of China (NSFC) (81171986), State{\textquoteright}s key Proiect of Research and Development Plan (2016YFC1303500), National Natural Science Foundation of China (NSFC) (81602024), National Natural Science Foundation of China (NSFC) (81771781), Ministry of Public Healthy (201501004). Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Taylor & Francis Group, LLC.",

year = "2018",

month = nov,

day = "2",

doi = "10.1080/2162402X.2018.1461303",

language = "English (US)",

volume = "7",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "11",

}

TY - JOUR

T1 - Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer

AU - Wang, Ruirui

AU - Yang, Li

AU - Zhang, Chaoqi

AU - Wang, Ruijie

AU - Zhang, Zhen

AU - He, Qianyi

AU - Chen, Xinfeng

AU - Zhang, Bin

AU - Qin, Zhihai

AU - Wang, Liping

AU - Zhang, Yi

N1 - Funding Information: This study was supported by grants from the National Natural Science Foundation of China (No.81171986, No. 81602024, No. 81771781), Funding from State's Key Project of Research and Development Plan (No. 2016YFC1303500), Research Grant from the Ministry of Public Health (No.201501004), Fundings for Creative Research Team of Henan Province, Creative Research Team of Higher Education of Henan Province. Funding Information: This study was supported by grants from the National Natural Science Foundation of China (No. 81171986, No. 81602024, No. 81771781), Funding from State’s Key Project of Research and Development Plan (No. 2016YFC1303500), Research Grant from the Ministry of Public Health (No. 201501004), Fundings for Creative Research Team of Henan Province, Creative Research Team of Higher Education of Henan Province. This study was supported by Creative Research Team of Henan Province Creative Research Team of Higher Education of Henan Province National Natural Science Foundation of China (NSFC) (81171986), State’s key Proiect of Research and Development Plan (2016YFC1303500), National Natural Science Foundation of China (NSFC) (81602024), National Natural Science Foundation of China (NSFC) (81771781), Ministry of Public Healthy (201501004). Publisher Copyright: © 2018, © 2018 Taylor & Francis Group, LLC.

PY - 2018/11/2

Y1 - 2018/11/2

N2 - Non-small cell lung cancer (NSCLC) accounts for the majority of all lung cancer cases, which is the leading cause of cancer deaths worldwide. IL-17░A, the major effector cytokine derived from Th17 cells, is a key cytokine in tumor pathogenesis and modulates tumor progression. We aimed to identify whether IL-17░A derived from Th17 cells promotes the progression of NSCLC. Here we found that the level of Th17 cells was increased in NSCLC and IL-17░A was mainly produced by CD4+ cells (Th17 cells) in NSCLC. IL-17░A enhanced the migration, invasion and stemness of NSCLC via STAT3/NF-κB/Notch1 signaling. Blockade of this signaling inhibited the migration, invasion and stemness of NSCLC mediated by IL-17░A. Th17 cells in NSCLC were closely associated with poor prognosis of NSCLC patients. Our results indicated that Th17 cell-derived IL-17░A plays an important role in tumor progression of NSCLC via STAT3/NF-κB/Notch1 signaling. Therefore, therapeutic strategies against this pathway would be valuable to be developed for NSCLC treatment.

AB - Non-small cell lung cancer (NSCLC) accounts for the majority of all lung cancer cases, which is the leading cause of cancer deaths worldwide. IL-17░A, the major effector cytokine derived from Th17 cells, is a key cytokine in tumor pathogenesis and modulates tumor progression. We aimed to identify whether IL-17░A derived from Th17 cells promotes the progression of NSCLC. Here we found that the level of Th17 cells was increased in NSCLC and IL-17░A was mainly produced by CD4+ cells (Th17 cells) in NSCLC. IL-17░A enhanced the migration, invasion and stemness of NSCLC via STAT3/NF-κB/Notch1 signaling. Blockade of this signaling inhibited the migration, invasion and stemness of NSCLC mediated by IL-17░A. Th17 cells in NSCLC were closely associated with poor prognosis of NSCLC patients. Our results indicated that Th17 cell-derived IL-17░A plays an important role in tumor progression of NSCLC via STAT3/NF-κB/Notch1 signaling. Therefore, therapeutic strategies against this pathway would be valuable to be developed for NSCLC treatment.

KW - Th17 cells

KW - Tumor microenvironment

KW - interleukin-17A (IL-17A)

KW - non-small cell lung cancer (NSCLC)

KW - tumor progression

UR - http://www.scopus.com/inward/record.url?scp=85052335049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052335049&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2018.1461303

DO - 10.1080/2162402X.2018.1461303

M3 - Article

C2 - 30377557

AN - SCOPUS:85052335049

SN - 2162-4011

VL - 7

JO - OncoImmunology

JF - OncoImmunology

IS - 11

M1 - e1461303

ER -

Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this